Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the treatment of both HIV-1 and HIV-2 infection.
Darunavir has been used in high-income settings since it was first approved by the US Food and Drug Administration (FDA)in 2006, but a historical lack of an affordable generic product co-formulated with ritonavir (DRV/r) has limited uptake in low-and middle-income countries (LMICs).
CHAI developed this clinical action memo to lay out information for national HIV programs considering the adoption and introduction of DRV/r (400/50 mg) and expanding access to this best-in-class medicine for people living with HIV needing a protease inhibitor (PI).